Form 10-Q · Quarterly report
Dow Inc. 10-Q, filed Jul 24, 2026
- Filed
- CIK
- 0001751788
- Accession no.
- 0001751788-26-000147
Summary
Dow Inc. reported second-quarter 2026 net sales of $12.1 billion, up 20% from a year earlier, and net income available to common stockholders of $721 million, or $0.99 per share, compared with a loss of $835 million, or $1.18 per share, a year earlier. The company also said Karen S. Carter was appointed CEO effective July 1, 2026, succeeding Jim Fitterling, who became Executive Chair, and recorded $503 million in restructuring and asset-related charges.
Key points
- Dow's second-quarter 2026 net sales rose 20% to $12.1 billion, with local price up 20% and volume down 1%.
- Dow's second-quarter net income available to common stockholders was $721 million, or $0.99 per share, versus a loss of $835 million, or $1.18 per share, in the second quarter of 2025.
- Dow's board declared a quarterly dividend of $0.35 per share, marking the 459th consecutive dividend paid by the company or its affiliates since 1912.
- Dow recorded $503 million in restructuring and asset-related charges in the second quarter of 2026, including severance costs tied to Transform to Outperform.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
ITEM 2. MANAGEMENT'S DISCUSSION OVERVIEW The following is a summary of the results for the three months ended June 30, 2026: •The Company reported net sales in the second quarter of 2026 of $12.1 billion, up 20 percent from $10.1 billion in the second quarter of 2025; Packaging & Specialty Plastics (up 27 percent), Industrial Intermediates & Infrastructure (up 14 percent) and Performance Materials & Coatings (up 11 percent). Net sales increased in all geographic regions; Latin America (up 41 percent), the U.S. & Canada and EMEAI (both up 20 percent), and Asia Pacific (up 5 percent). …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.